ProCE Banner Activity

OpACIN-neo and PRADO: Effect of Response-Directed Treatment Personalization on Survival After Neoadjuvant Immune Checkpoint Blockade in Stage III Melanoma

Capsule Summary
Conference Coverage

Omission of TLND in patients with high-risk melanoma who achieve a major pathologic response to neoadjuvant ICI therapy does not negatively affect RFS or DMFS outcomes, but adjuvant systemic therapy appears to improve RFS or DMFS outcomes in patients who achieved a pathologic nonresponse to neoadjuvant ICI therapy.

Released: June 09, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc